Catherine Arnold

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings read more

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

The U.S. case is more important because of the economic implications. It (the U.K. ruling) is a nice psychological boost read more

The U.S. case is more important because of the economic implications. It (the U.K. ruling) is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

The U.S. case is more important because of the economic implications. [The U.K. ruling] is a nice psychological boost, but read more

The U.S. case is more important because of the economic implications. [The U.K. ruling] is a nice psychological boost, but you can't extrapolate the U.S. ruling from this because of the different legal standards.

This is half the savings that Pfizer achieved with its recently announced program.

This is half the savings that Pfizer achieved with its recently announced program.

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to read more

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.